标题
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
作者
关键词
-
出版物
Cancer Control
Volume 21, Issue 3, Pages 231-237
出版商
SAGE Publications
发表日期
2017-08-30
DOI
10.1177/107327481402100308
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Defining the molecular tumor margin regions of clear cell renal carcinoma tissues by MALDI-MS imaging of lipid and glycan species.
- (2017) Richard Drake et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
- (2013) S A Quezada et al. BRITISH JOURNAL OF CANCER
- Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity
- (2013) Alan G. Ramsay BRITISH JOURNAL OF HAEMATOLOGY
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer
- (2013) Julie R. Brahmer JOURNAL OF CLINICAL ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Immune alterations and emerging immunotherapeutic approaches in lung cancer
- (2012) Constantin A Dasanu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer
- (2012) Patricia A. Tang et al. Current Oncology Reports
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Gene Signature in Melanoma Associated With Clinical Activity
- (2010) Thomas F. Gajewski et al. CANCER JOURNAL
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology
- (2010) Nobuyoshi Hiraoka International Journal of Clinical Oncology
- Immune Regulation of Cancer
- (2010) Mary L. Disis JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?
- (2009) Jose L Perez-Gracia et al. Immunotherapy
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
- (2008) Hazem Ghebeh et al. BMC CANCER
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More